Elan Corp, plc (ADR) (ELN)

michjksn (< 20) Submitted: 2/27/2009 1:42:57 PM : Start Price: $6.26 ELN Score: +48.79

Historically poorly run company. One product which causes death all too often/terrible press. No products on horizon, including Bap, worth anything other than being money pits for underachievement. What R&D there was, has been all but killed off due to debt load, which is overwhelming and coming due in the near future. Convoluted ownership of company parts precludes any sale.

buckywildcat (< 20) Submitted: 1/19/2009 9:39:31 PM : Start Price: $7.15 ELN Score: +44.99

With the additional time being added on to their ongoing clinical trial for AD, the mounting debt becomes increasingly problematic. Additional delays or unanticipated safety issues could end up bringing ELN down.

supercoffee (81.00) Submitted: 7/31/2008 5:51:23 PM : Start Price: $11.03 ELN Score: +32.55

get lowing

zim3888 (< 20) Submitted: 5/16/2008 11:55:57 PM : Start Price: $27.04 ELN Score: +56.99

12.00 dollar stock by 2009 shoooooooort it

RextonGroup (58.45) Submitted: 4/14/2008 2:55:04 PM : Start Price: $20.89 ELN Score: +56.18

Technical: long term trend - Down; short term trend - Down;
Options: 09-Apr Puts:4,140 Calls:12,392 P/C = 0.33 - Contrarian Short
Trade time frame: 1-3 days.

morningstarboy (< 20) Submitted: 2/21/2008 1:04:03 PM : Start Price: $24.00 ELN Score: +58.90

As of close of business on 2/20/08, this was a 1-star Morningstar stock trading at more than double its Morningstar fair value.

GotFord (< 20) Submitted: 10/12/2007 5:01:10 PM : Start Price: $24.70 ELN Score: +48.59

Need some good news.

Toast82 (94.91) Submitted: 6/15/2007 8:38:39 PM : Start Price: $21.55 ELN Score: +46.59

With all biotechs there are many steps to final approval. Take a look at Dendreon stock to get a feeling. The stock is currently up and in the long run will pay off but in short-term with any stock requiring FDA multi-step approval moving down is not only possible but probable.

SirVoor (40.39) Submitted: 1/3/2007 12:07:01 PM : Start Price: $14.49 ELN Score: +38.43

Good products can’t over come bad management.

Providence (< 20) Submitted: 10/19/2006 12:05:27 PM : Start Price: $15.54 ELN Score: +45.42

Elan not only has Tysabri for MS, they have a monster Alzheimer's program. If all goes well, they will be first to market with one or two dominating therapies. This is a 100 billion market. They will own the space.

On top of MS and AD, look for developments in Chrones, RH, and Parkinsons. Icing on the cake, a fast-developing nano program with dozens of drugs in development. Elan currently makes just under 5% royalties on these partnerships. Look for that percentage to increase as the benefits of nano delivery become evident over the next several years.